Peroxisome proliferator-activated receptor gamma ligand-induced growth inhibition of human hepatocellular carcinoma.
Peroxisome proliferator-activated receptor gamma (PPARgamma) ligands have been implicated in the growth inhibition and differentiation of certain human cancers with diverse tissue origin. In this study, expression of PPARgamma in human hepatocellular carcinoma (HCC) and the effect of PPARgamma ligands on HCC cells were investigated in vitro using Hep G2, HuH-7, KYN-1 and KYN-2 cell lines. All cell lines were found to express functionally active PPARgamma and a marked growth inhibition was induced by thiazolidinedione ligands troglitazone, and pioglitazone as well as with its natural ligand 15-deoxy-Delta(12,14)-prostaglandin J(2). The growth inhibitory effect was associated with a dose-dependent inhibition of DNA synthesis, cell cycle progression and alpha fetoprotein expression.
Rumi
M A
MA
Second Department of Internal Medicine, Shimane Medical University, Izumo, Japan.
Sato
H
H
Ishihara
S
S
Kawashima
K
K
Hamamoto
S
S
Kazumori
H
H
Okuyama
T
T
Fukuda
R
R
Nagasue
N
N
Kinoshita
Y
Y
D006528:Carcinoma, Hepatocellular / Q000473:pathology / Q000503:physiopathology*; D002453:Cell Cycle / Q000187:drug effects; D002454:Cell Differentiation; D002455:Cell Division; D004305:Dose-Response Relationship, Drug; D006801:Humans; D008024:Ligands; D008113:Liver Neoplasms / Q000473:pathology / Q000503:physiopathology*; D018160:Receptors, Cytoplasmic and Nuclear; D014157:Transcription Factors; D014407:Tumor Cells, Cultured
D008024:Ligands; D018160:Receptors, Cytoplasmic and Nuclear; D014157:Transcription Factors